The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,968,786 in first-year total cost, median $770,594.
Most frequent study sections
- Special Emphasis Panel[ZAI1 BLG-M (J1)]5
Most frequent institutions
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
- HARVARD MEDICAL SCHOOL1
- TEXAS BIOMEDICAL RESEARCH INSTITUTE1
- UNIVERSITY OF CALIFORNIA, SAN DIEGO1
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas1R01AI176309-01 | RESTREPO, BLANCA ITORRELLES, JORDI BYOTEBIENG, MARCEL | TEXAS BIOMEDICAL RESEARCH INSTITUTE, TX | $956,440 | ZAI1 |
| 2023 | Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage1R01AI176407-01 | O'DONNELL, MAX | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $800,726 | ZAI1 |
| 2023 | An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis1R01AI176498-01 | FARHAT, MAHA | HARVARD MEDICAL SCHOOL, MA | $770,594 | ZAI1 |
| 2023 | Automated Sequencing for Culture-free Diagnosis of Drug Resistant TB1R01AI176401-01 | COLMAN, REBECCA ELIZABETHRODWELL, TIMOTHY CHARLES | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $764,235 | ZAI1 |
| 2023 | Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker1R01AI176409-01 | KATO-MAEDA, MIDORI | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $676,791 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.